Contingency Management for Smoking Cessation
This study is testing a new way to help people quit smoking by encouraging them to use a medication called varenicline and participate in counseling. All participants will receive 12 weeks of varenicline and referrals to their state tobacco quitline. Some participants will also receive "Health Rewards" (Contingency Management), which means they could earn financial incentives for taking their medication and attending counseling sessions. We are looking for 40 adults, aged 18 or older, who live in Kansas, smoke at least one cigarette a day, and can read English and use a mobile phone for text messages. The main goal is to see if this approach is practical and acceptable, and to measure how many quitline calls are completed and how much varenicline is taken over 12 weeks. The study status is currently unclear.
- Study design
- This is a pilot interventional study with 40 participants. It is a randomized clinical trial, meaning participants will be assigned by chance to either the Health Rewards group or the Control group.
- What's involved
- Participants will receive 12 weeks of varenicline and referrals to a state tobacco quitline. The study will measure how many quitline calls are completed and how much varenicline is taken over 12 weeks.
- Compensation
- Participants in the Health Rewards group will receive financial incentives for taking medication and attending counseling sessions. Payments will be automated and dispensed daily using a reloadable debit card.
- Follow-up
- The study will measure outcomes at Week 3 and Week 12, focusing on the proportion of quitline calls completed and varenicline pills taken.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Contingency Management to Promote Smoking Cessation: A Pilot Randomized Clinical Trial
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Feasibility outcomesWeek 3 to 12
Feasibility endpoints include: (1) the proportion of eligible subjects who subsequently enroll; and (2) the proportion of enrolled subjects who complete the 3-week, 6-week, and 12-week assessments.
- Proportion of quitline calls completedWeek 12
Completion of the five quitline calls according to Kansas quitline reports
- Proportion of varenicline pills takenWeek 12
Varenicline intake over 12 weeks of treatment according to the smart pill dispenser counting